Capreomycin Sulfate and Duvelisib

• Generic Name: capreomycin
• Dosage Forms: n.a.
• Other Brand Names: Capastat Sulfate

Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents.

Second-line agent used in treatment of drug-resistant TB caused by Mycobacterium tuberculosis known or presumed to be susceptible to capreomycin.

For initial treatment of active TB caused by drug-susceptible M. tuberculosis, recommended multiple-drug regimens consist of an initial intensive phase (2 months) and a continuation phase (4 or 7 months). Although the usual duration of treatment for drug-susceptible pulmonary and extrapulmonary TB (except disseminated infections and TB meningitis) is 6–9 months, ATS, CDC, and IDSA state that completion of treatment is determined more accurately by the total number of doses and should not be based solely on the duration of therapy. A longer duration of treatment (e.g., 12–24 months) usually is necessary for infections caused by drug-resistant M. tuberculosis.

Patients with treatment failure or drug-resistant M. tuberculosis, including multidrug-resistant (MDR) TB (resistant to both isoniazid and rifampin) or extensively drug-resistant (XDR) TB (resistant to both isoniazid and rifampin and also resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial such as capreomycin, kanamycin, or amikacin), should be referred to or managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.

• Generic Name: duvelisib
• Dosage Forms: n.a.
• Other Brand Names: Copiktra

Duvelisib is used to treat adults with chronic lymphocytic leukemia or small lymphocytic leukemia. Duvelisib is also used to treat follicular lymphoma.

Duvelisib is given after at least two other cancer treatments did not work or have stopped working.

Duvelisib may also be used for purposes not listed in this medication guide.